HC Wainwright & Co. Maintains Buy on Legend Biotech, Raises Price Target to $82
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Mitchell Kapoor maintains a Buy rating on Legend Biotech (NASDAQ:LEGN) and raises the price target from $77 to $82.
June 06, 2023 | 10:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains Buy rating on Legend Biotech and raises the price target from $77 to $82.
The news of HC Wainwright & Co. maintaining a Buy rating and raising the price target for Legend Biotech is positive for the company's stock. This indicates that the analyst believes in the company's growth potential and expects the stock price to rise in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100